Active Ingredient(s): Mobocertinib
FDA Approved: * September 15, 2021
Pharm Company: * TAKEDA PHARMS USA
Category: Cancer

Mobocertinib, sold under the brand name Exkivity, is used for the treatment of non-small cell lung cancer.[2][3] The most common side effects include diarrhea, rash, nausea, stomatitis, vomiting, decreased appetite, paronychia, fatigue, dry skin, and musculoskeletal pain.[2] Mobocertinib is a small molecule tyrosine kinase inhibitor. Its molecular target is epidermal growth factor receptor (EGFR) bearing mutations in the exon 20 region.[... [wikipedia]

* May have multiple approval dates, manufacturers, or labelers.

Dosage List

Exkivity 40 mg Oral Capsule
NDC: 63020-040
Takeda Pharmaceuticals America, Inc.